Integrative Modeling of Transcriptional Regulation in Response to Autoimmune Disease Therapies

Total Page:16

File Type:pdf, Size:1020Kb

Integrative Modeling of Transcriptional Regulation in Response to Autoimmune Disease Therapies Integrative Modeling of Transcriptional Regulation in Response to Autoimmune Disease Therapies Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) vorgelegt dem Rat der Biologisch-Pharmazeutischen Fakultät der Friedrich-Schiller-Universität Jena von Diplom-Bioinformatiker Michael Hecker geboren am 6. April 1982 in Erfurt Die vorgelegte Arbeit, finanziert durch das Bundesministerium für Bildung und Forschung (Grant 0313692D), wurde am Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. - Hans-Knöll-Institut (HKI) unter der Leitung von PD Dr. Reinhard Guthke (Abteilung Systembiologie / Bioinformatik) im Zeitraum November 2006 bis Januar 2010 angefertigt. Table of contents I Table of contents Abbreviations.................................................................................................................III 1. Introduction......................................................................................................................1 1.1. Gene regulatory network modeling.............................................................................1 1.2. Autoimmune diseases..................................................................................................4 1.3. Objectives and experimental approach........................................................................8 2. Overview of manuscripts...............................................................................................11 3. Manuscript I....................................................................................................................16 Hecker M, Lambeck S, Töpfer S, van Someren E, Guthke R. Gene regulatory network inference: data integration in dynamic models - a review. Biosystems 2009, 96(1):86-103. 4. Manuscript II..................................................................................................................35 Hecker M, Goertsches RH, Engelmann R, Thiesen HJ, Guthke R. Integrative modeling of transcriptional regulation in response to antirheumatic therapy. BMC Bioinformatics 2009, 10:262. 5. Manuscript III.................................................................................................................54 Goertsches RH, Hecker M, Koczan D, Serrano-Fernández P, Möller S, Thiesen HJ, Zettl UK. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010, 11(2):147-161. 6. Manuscript IV.................................................................................................................70 Hecker M, Goertsches RH, Fatum C, Koczan D, Thiesen HJ, Guthke R, Zettl UK. Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. Pharmacogenomics J. submitted January 25, 2010. 7. Discussion......................................................................................................................104 Table of contents II 7.1. Discussion of main results.......................................................................................104 7.2. Discussion of methods.............................................................................................107 7.2.1. Experimental approach......................................................................................107 7.2.2. Microarray data preprocessing..........................................................................108 7.2.3. Integrative network inference............................................................................109 7.2.4. Evaluation of inference performance.................................................................111 7.3. Open issues and outlook..........................................................................................113 7.3.1. Prediction of clinical responses.........................................................................113 7.3.2. Further development of TILAR.........................................................................114 7.4. Concluding remarks.................................................................................................116 8. Summary.......................................................................................................................118 9. Zusammenfassung........................................................................................................120 References......................................................................................................................122 Appendix........................................................................................................................127 Danksagung...................................................................................................................141 Ehrenwörtliche Erklärung...........................................................................................142 Tabellarischer Lebenslauf...........................................................................................143 Abbreviations III Abbreviations ACPA anti-citrullinated protein/peptide antibody ACR American College of Rheumatology CDF chip definition file CSF cerebrospinal fluid DAS disease activity score DMARD disease-modifying antirheumatic drug DREAM dialogue on reverse-engineering assessment and methods EDSS expanded disability status scale GO Gene Ontology GRN gene regulatory network HLA human leukocyte antigen IFN-β interferon-beta IRF IFN regulatory factor LARS least angle regression Lasso least absolute shrinkage and selection operator MAID MA-plot-based signal intensity-dependent fold-change criterion MHC major histocompatibility complex MRI magnetic resonance imaging MS multiple sclerosis OLS ordinary least squares PBMC peripheral blood mononuclear cells PPI protein-protein interaction RA rheumatoid arthritis RF rheumatoid factor RNAP RNA polymerase ROC recall-precision curve RPC receiver operating characteristic TF transcription factor TFBS transcription factor binding site TILAR TFBS-integrating least angle regression TNF-α tumor necrosis factor-alpha Introduction 1 1. Introduction At the heart of multicellular life are the complex interactions between genes, proteins and metabolites. These interactions give rise to the function and behavior of biological systems. To study and understand such systems as a whole abstractions are needed such as the concept of networks, in which molecules are represented as nodes and interactions or causal influences are represented by edges. The reconstruction of biomolecular networks from experimental data and subsequent network analysis is a challenging and active field of research. The major focus of the present dissertation is on the inference of gene regulatory networks (GRNs). 1.1. Gene regulatory network modeling Gene expression is mainly regulated at the level of DNA transcription by proteins called transcription factors (TFs). These TFs specifically bind short DNA sequence motifs at the regulatory region of their target genes. In doing so, they control the recruitment of RNA polymerase, which reads the DNA and transcribes it into RNA. However, gene regulation is a far more complex multi-layered process. Any step of gene expression may be modulated, from the RNA synthesis to the post-translational modification of proteins. Many genes are (directly oder indirectly) involved in these gene regulatory mechanisms, and therefore it is reasonable to regard genes as nodes in a network of mutual regulatory interactions. The introduction of DNA microarrays in the mid-1990s offered the possibility to simultaneously measure the levels of thousands of RNA transcripts in a single sample of cells or tissues. Since then, researchers utilized the growing amount of large-scale gene expression data as input for algorithms to infer, or "reverse-engineer", the regulatory interaction structure of genes [1-3]. When inferring models of transcriptional regulation solely from gene expression data, one typically seeks for influences between RNA transcripts. In this case, the expression levels of each gene are explained by the expression levels of other genes. By construction, such GRN models do not generally describe physical interactions as transcripts rather exert their regulatory effects indirectly through the action of proteins, metabolites and effects on the cell environment (figure 1). Therefore, these models can be difficult to interpret in terms of real physical interactions, and the implicit description of hidden regulatory factors may limit the reliability of the inference results. To overcome these issues and support the network reconstruction it is necessary to integrate additional biological information. Diverse types of data (e.g. protein-protein and protein- Introduction 2 Figure 1. Gene regulation is carried out by interactions of RNA molecules, proteins and metabolites. (A) Simplified illustration of an example GRN where gene "3" encodes a membrane-bound metabolite transporter protein (green shape). The metabolite (blue triangle) that is imported by this protein binds a TF (orange shape). The activated TF binds the DNA and together with RNA polymerase (RNAP) initiates the transcription of gene "2". Hence, the expression of gene "2" is influenced by the other two gene transcripts (red lines). (B) A graph model of the network in (A). Because the model is inferred from measurements of RNA transcripts only, it implicitly captures the regulatory mechanisms at the
Recommended publications
  • Metallothionein Monoclonal Antibody, Clone N11-G
    Metallothionein monoclonal antibody, clone N11-G Catalog # : MAB9787 規格 : [ 50 uL ] List All Specification Application Image Product Rabbit monoclonal antibody raised against synthetic peptide of MT1A, Western Blot (Recombinant protein) Description: MT1B, MT1E, MT1F, MT1G, MT1H, MT1IP, MT1L, MT1M, MT2A. Immunogen: A synthetic peptide corresponding to N-terminus of human MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1IP, MT1L, MT1M, MT2A. Host: Rabbit enlarge Reactivity: Human, Mouse Immunoprecipitation Form: Liquid Enzyme-linked Immunoabsorbent Assay Recommend Western Blot (1:1000) Usage: ELISA (1:5000-1:10000) The optimal working dilution should be determined by the end user. Storage Buffer: In 20 mM Tris-HCl, pH 8.0 (10 mg/mL BSA, 0.05% sodium azide) Storage Store at -20°C. Instruction: Note: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. Datasheet: Download Applications Western Blot (Recombinant protein) Western blot analysis of recombinant Metallothionein protein with Metallothionein monoclonal antibody, clone N11-G (Cat # MAB9787). Lane 1: 1 ug. Lane 2: 3 ug. Lane 3: 5 ug. Immunoprecipitation Enzyme-linked Immunoabsorbent Assay ASSP5 MT1A MT1B MT1E MT1F MT1G MT1H MT1M MT1L MT1IP Page 1 of 5 2021/6/2 Gene Information Entrez GeneID: 4489 Protein P04731 (Gene ID : 4489);P07438 (Gene ID : 4490);P04732 (Gene ID : Accession#: 4493);P04733 (Gene ID : 4494);P13640 (Gene ID : 4495);P80294 (Gene ID : 4496);P80295 (Gene ID : 4496);Q8N339 (Gene ID : 4499);Q86YX0 (Gene ID : 4490);Q86YX5
    [Show full text]
  • CD56+ T-Cells in Relation to Cytomegalovirus in Healthy Subjects and Kidney Transplant Patients
    CD56+ T-cells in Relation to Cytomegalovirus in Healthy Subjects and Kidney Transplant Patients Institute of Infection and Global Health Department of Clinical Infection, Microbiology and Immunology Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy by Mazen Mohammed Almehmadi December 2014 - 1 - Abstract Human T cells expressing CD56 are capable of tumour cell lysis following activation with interleukin-2 but their role in viral immunity has been less well studied. The work described in this thesis aimed to investigate CD56+ T-cells in relation to cytomegalovirus infection in healthy subjects and kidney transplant patients (KTPs). Proportions of CD56+ T cells were found to be highly significantly increased in healthy cytomegalovirus-seropositive (CMV+) compared to cytomegalovirus-seronegative (CMV-) subjects (8.38% ± 0.33 versus 3.29%± 0.33; P < 0.0001). In donor CMV-/recipient CMV- (D-/R-)- KTPs levels of CD56+ T cells were 1.9% ±0.35 versus 5.42% ±1.01 in D+/R- patients and 5.11% ±0.69 in R+ patients (P 0.0247 and < 0.0001 respectively). CD56+ T cells in both healthy CMV+ subjects and KTPs expressed markers of effector memory- RA T-cells (TEMRA) while in healthy CMV- subjects and D-/R- KTPs the phenotype was predominantly that of naïve T-cells. Other surface markers, CD8, CD4, CD58, CD57, CD94 and NKG2C were expressed by a significantly higher proportion of CD56+ T-cells in healthy CMV+ than CMV- subjects. Functional studies showed levels of pro-inflammatory cytokines IFN-γ and TNF-α, as well as granzyme B and CD107a were significantly higher in CD56+ T-cells from CMV+ than CMV- subjects following stimulation with CMV antigens.
    [Show full text]
  • UMP/CMPK Is Not the Critical Enzyme in the Metabolism of Pyrimidine Ribonucleotide and Activation of Deoxycytidine Analogs in Human RKO Cells
    UMP/CMPK Is Not the Critical Enzyme in the Metabolism of Pyrimidine Ribonucleotide and Activation of Deoxycytidine Analogs in Human RKO Cells Rong Hu1, Wing Lam1, Chih-Hung Hsu1,2, Yung-Chi Cheng* 1 Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America, 2 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China Abstract Background: Human UMP/CMP kinase was identified based on its enzymatic activity in vitro. The role of this protein is considered critical for the maintenance of pyrimidine nucleotide pool profile and for the metabolism of pyrimidine analogs in cells, based on the in vitro study of partially purified enzyme and recombinant protein. However, no detailed study has yet addressed the role of this protein in nucleotide metabolism in cells. Methodology/Principal Findings: Two stable cell lines in which UMP/CMP kinase (mRNA: AF087865, EC 2.7.4.14) can be either up-regulated or down-regulated were developed using Tet-On Gene Expression Systems. The amount and enzymatic activity of UMP/CMP kinase extracted from these two cell lines can be induced up by 500% or down by 95–98%. The ribonucleotides of endogenous pyrimidine as well as the metabolism of exogenous natural pyrimidine nucleosides and their analogs were not susceptible to the altered amount of UMP/CMP kinase in these two stable RKO cell lines. The level of incorporation of pyrimidine nucleoside analogs, such as gemcitabine (dFdC) and troxacitabine (L-OddC), into cellular DNA and their potency in inhibiting cell growth were not significantly altered by up-regulation or down-regulation of UMP/CMP kinase expression in cells.
    [Show full text]
  • Transcriptional Regulation Differs in Affected Facioscapulohumeral Muscular Dystrophy Patients Compared to Asymptomatic Related Carriers
    University of Massachusetts Medical School eScholarship@UMMS Wellstone Center for FSHD Publications Wellstone Center for FSHD 2009-04-14 Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers Patricia Arashiro University of Sao Paulo Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/wellstone_pubs Part of the Cell Biology Commons, Developmental Biology Commons, Molecular Biology Commons, Molecular Genetics Commons, Musculoskeletal Diseases Commons, and the Nervous System Diseases Commons Repository Citation Arashiro P, Eisenberg I, Kho AT, Cerqueira AM, Canovas M, Silva HC, Pavanello RC, Verjovski-Almeida S, Kunkel LM, Zatz M. (2009). Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. Wellstone Center for FSHD Publications. https://doi.org/10.1073/pnas.0901573106. Retrieved from https://escholarship.umassmed.edu/ wellstone_pubs/18 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Wellstone Center for FSHD Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers Patricia Arashiroa, Iris Eisenbergb, Alvin T. Khoc, Antonia M. P. Cerqueiraa, Marta
    [Show full text]
  • Identification and Analysis of Single-Nucleotide Polymorphisms in the Gemcitabine Pharmacologic Pathway
    The Pharmacogenomics Journal (2004) 4, 307–314 & 2004 Nature Publishing Group All rights reserved 1470-269X/04 $30.00 www.nature.com/tpj ORIGINAL ARTICLE Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway AK Fukunaga1 ABSTRACT 2 Significant variability in the antitumor efficacy and systemic toxicity of S Marsh gemcitabine has been observed in cancer patients. However, there are 1 DJ Murry currently no tools for prospective identification of patients at risk for TD Hurley3 untoward events. This study has identified and validated single-nucleotide HL McLeod2 polymorphisms (SNP) in genes involved in gemcitabine metabolism and transport. Database mining was conducted to identify SNPs in 14 genes 1Department of Clinical Pharmacy and Pharmacy involved in gemcitabine metabolism. Pyrosequencing was utilized to Practice, Purdue University, W. Lafayette, IN, determine the SNP allele frequencies in genomic DNA from European and 2 USA; Departments of Medicine, Genetics, and African populations (n ¼ 190). A total of 14 genetic variants (including 12 Molecular Biology and Pharmacology, Washington University School of Medicine and SNPs) were identified in eight of the gemcitabine metabolic pathway genes. the Siteman Cancer Center, St Louis, MO, USA; The majority of the database variants were observed in population samples. 3Department of Biochemistry and Molecular Nine of the 14 (64%) polymorphisms analyzed have allele frequencies that Biology, Indiana University School of Medicine, were found to be significantly different between the European and African Indianapolis, IN, USA populations (Po0.05). This study provides the first step to identify markers Correspondence: for predicting variability in gemcitabine response and toxicity. Dr HL McLeod, Washington University The Pharmacogenomics Journal (2004) 4, 307–314.
    [Show full text]
  • Nutrient Health and EROEN Compounds Resegsterixsteextics: Production * Gets Cartrai, Agairaxxxix
    US 2011 O153221A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0153221 A1 Stefanon et al. (43) Pub. Date: Jun. 23, 2011 (54) DIAGNOSTIC SYSTEM FOR SELECTING (52) U.S. Cl. .......................................................... 702/19 NUTRITION AND PHARMACOLOGICAL PRODUCTS FOR ANIMALS (57) ABSTRACT (76) Inventors: Bruno Stefanon, Martignacco (IT): W.Year Jean Dodds.Odds, Santa Monica,IVIon1ca, CA An analysis of the profile of a non-human animal comprises: a) providing a genotypic database to the species of the non (21) Appl. No.: 12/927,769 human animal Subject or a selected group of the species; b obtaining animal data; c) correlating the database of a) with (22) Filed:1-1. Nov. 19, 2010 the data ofb) to determinea relationshipp between the database of a) and the data of b); c) determining the profile of the Related U.S. Application Data animal based on the correlating step; and d) determining a (63)63) ContinuationConti offaroplication application No. 12/316.824,:4'. filed'O geneticmolecular profile dietary based signature on the being molecular a variation dietary of signature, expression the of Dec. 16, 2008, now Pat. No. 7,873,482. a set of genes which may differ for the genotype of each O O animal or a group of animals Nutrition and pharmalogical Publication Classification assessments are made. Reporting the determination is by the (51) Int. Cl. Internet, and payment for the report is obtained through the G06F 9/00 (2011.01) Internet. 38s. 4 gas registics, $88's *.icisixxxiiserscies: 8 texrigixi exsix * processire statisy • Essex: 88& goEffect onXXXXWWYYX Nutrient health and EROEN Compounds resegsterixsteextics: production * gets cartrai, agairaxxxix.
    [Show full text]
  • UC Riverside UCR Honors Capstones 2019-2020
    UC Riverside UCR Honors Capstones 2019-2020 Title Development of a Method for Heterologous Expression of Moss Methyltransferases in Pichia Pastoris Yeast Permalink https://escholarship.org/uc/item/4f71h39k Author Fogel, Dustin Publication Date 2021-01-08 Data Availability The data associated with this publication are within the manuscript. eScholarship.org Powered by the California Digital Library University of California By A capstone project submitted for Graduation with University Honors University Honors University of California, Riverside APPROVED _______________________________________________ Dr. Department of _______________________________________________ Dr. Richard Cardullo, Howard H Hays Jr. Chair, University Honors Abstract Acknowledgements: I would like to thanks to Anjin Huang for her extensive work on designing and leading a significant part of the transformation of new Pichia cultures. I would also like to thank Dr. Eugene A. Nothnagel, my faculty mentor, for his unending dedication, guidance, and support throughout both this capstone project and my time as an undergraduate student at UCR. Additionally, I would like to thank Dr. Martha L. Orozco-Cárdenas for aiding in this project by donating both lab space and time to developing this project. Finally, I would like to thank other student collaborators, Carlos Aguilar, James Yen, Maivy Ngoc Le, and others in assisting with conducting many of the experiments that culminated in this capstone project. 1 Table of Contents Abstract_____________________________________________________________________
    [Show full text]
  • Ggbio: Visualization Toolkits for Genomic Data
    ggbio: visualization toolkits for genomic data 1 Tengfei Yin [email protected] May 19, 2021 Contents 1 Getting started............................4 1.1 Citation.................................4 1.2 Introduction ..............................4 2 Case study: building your first tracks..............6 2.1 Add an ideogram track ........................6 2.2 Add a gene model track .......................7 2.2.1 Introduction ...........................7 2.2.2 Make gene model from OrganismDb object ............7 2.2.3 Make gene model from TxDb object ................ 11 2.2.4 Make gene model from EnsDb object ............... 12 2.2.5 Make gene model from GRangesList object ............ 16 2.3 Add a reference track ........................ 19 2.3.1 Semantic zoom.......................... 19 2.4 Add an alignment track ....................... 20 2.5 Add a variants track ......................... 25 2.6 Building your tracks ......................... 28 3 Simple navigation .......................... 30 4 Overview plots............................ 32 4.1 how to make circular plots ...................... 32 4.1.1 Introduction ........................... 32 4.1.2 Buidling circular plot layer by layer................. 32 2 ggbio:visualization toolkits for genomic data 4.1.3 Complex arragnment of plots ................... 39 4.2 How to make grandlinear plots ................... 41 4.2.1 Introduction ........................... 41 4.2.2 Corrdinate genome ........................ 43 4.2.3 Convenient plotGrandLinear function ............... 43 4.2.4 How to highlight some points? .................. 45 4.3 How to make stacked karyogram overview plots ......... 46 4.3.1 Introduction ........................... 46 4.3.2 Create karyogram temlate .................... 46 4.3.3 Add data on karyogram layout................... 48 4.3.4 Add more data using layout_karyogram function .......... 51 4.3.5 More flexible layout of karyogram ................
    [Show full text]
  • Precise and Sustained Gene Silencing in CD4+ Cells Using Designer Epigenome Modifiers As a Therapeutic Approach to Treat HIV Infection
    Precise and sustained gene silencing in CD4+ cells using designer epigenome modifiers as a therapeutic approach to treat HIV infection Inaugural-Dissertation to obtain the Doctoral Degree Faculty of Biology, Albert-Ludwigs-Universität Freiburg im Breisgau presented by Tafadzwa Mlambo born in Harare, Zimbabwe Freiburg im Breisgau February 2018 Dekanin: Prof. Dr. Bettina Warscheid Promotionsvorsitzender: Prof. Dr. Andreas Hiltbrunner Betreuer der Arbeit: Dr. Claudio Mussolino Referent: Prof. Dr. Toni Cathomen Ko-Referent: Prof. Dr. Peter Stäheli Drittprüfer: Dr. Giorgos Pyrowolakis Datum der mündlichen Prüfung: 27.04.2018 iii Table of Contents TABLE OF CONTENTS TABLE OF CONTENTS III ABSTRACT VIII 1. INTRODUCTION 11 1.1 HIV BURDEN AND EPIDEMIOLOGY 11 1.2 HIV LIFE CYCLE AND TROPISM 12 1.3 HIV TREATMENT 14 1.4 CCR5 AND CXCR4 AS TARGETS OF ANTI-HIV THERAPY 15 1.5 DESIGNER NUCLEASE TECHNOLOGY 17 1.5.1 Zinc finger nucleases 19 1.5.2 Transcription activator-like effector nucleases 20 1.5.3 RNA-guided endonucleases 21 1.6 HIV GENE THERAPY 22 1.7 OFF-TARGET EFFECTS 25 1.8 DELIVERY 27 1.9 EPIGENETIC REGULATION 30 1.9.1 Gene expression 30 1.9.2 Transcriptional regulation of gene expression 31 1.9.3 Targeted transcription activation 32 1.9.4 Targeted transcription repression 33 1.9.5 Epigenome editing 36 1.9.6 DNA methylation 38 iv Table of Contents 1.9.7 Designer epigenome modifiers 40 1.10 AIM AND OBJECTIVES OF PHD THESIS 42 2. MATERIALS AND METHODS 44 2.1 STANDARD MOLECULAR BIOLOGY METHODS 44 2.1.1 Restriction digest 44 2.1.2 Ligation 44 2.1.3 Polymerase
    [Show full text]
  • (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation
    Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds.
    [Show full text]
  • CHMP5 Antibody (C-Term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap18536b
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CHMP5 Antibody (C-term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP18536b Specification CHMP5 Antibody (C-term) - Product Information Application WB,E Primary Accession Q9NZZ3 Other Accession Q4QQV8, Q9D7S9, NP_057494.3 Reactivity Human Predicted Mouse, Rat Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Antigen Region 178-204 CHMP5 Antibody (C-term) - Additional Information CHMP5 Antibody (C-term) (Cat. #AP18536b) western blot analysis in MDA-MB231 cell line Gene ID 51510 lysates (35ug/lane).This demonstrates the Other Names CHMP5 antibody detected the CHMP5 protein Charged multivesicular body protein 5, (arrow). Chromatin-modifying protein 5, SNF7 domain-containing protein 2, Vacuolar protein sorting-associated protein 60, CHMP5 Antibody (C-term) - Background Vps60, hVps60, CHMP5, C9orf83, SNF7DC2 CHMP5 belongs to the chromatin-modifying Target/Specificity protein/charged This CHMP5 antibody is generated from multivesicular body protein (CHMP) family. rabbits immunized with a KLH conjugated These proteins are synthetic peptide between 178-204 amino components of ESCRT-III (endosomal sorting acids from the C-terminal region of human complex required for CHMP5. transport III), a complex involved in degradation of surface Dilution receptor proteins and formation of endocytic WB~~1:1000 multivesicular bodies (MVBs). Some CHMPs have both nuclear and Format cytoplasmic/vesicular Purified polyclonal antibody supplied in PBS distributions, and one such CHMP, CHMP1A with 0.09% (W/V) sodium azide. This (MIM 164010), is required antibody is purified through a protein A for both MVB formation and regulation of cell column, followed by peptide affinity cycle progression purification.
    [Show full text]
  • Anglemetry of Neural Axis Cell Differentiation Genes by Structural Pressurotopy of DNA Loop Strand Segment Tropy in Reference to Tissue Macro-Compliance Hemant Sarin
    Sarin Translational Medicine Communications (2019) 4:13 Translational Medicine https://doi.org/10.1186/s41231-019-0045-4 Communications RESEARCH Open Access Anglemetry of neural axis cell differentiation genes by structural pressurotopy of DNA loop strand segment tropy in reference to tissue macro-compliance Hemant Sarin Abstract Background: Even as the eukaryotic stranded DNA is known to heterochromatinize at the nuclear envelope in response to mechanical strain, the precise mechanistic basis for alterations in chromatin gene transcription in differentiating cell lineages has been difficult to determine due to limited spatial resolution for detection of shifts in reference to a specific gene in vitro. In this study, heterochromatin shift during euchromatin gene transcription has been studied by parallel determinations of DNA strand loop segmentation tropy nano-compliance (esebssiwaagoTQ units, linear nl), gene positioning angulation in linear normal two- 0 dimensional (2-D) z, y-vertical plane (anglemetry, ), horizontal alignment to the z, x-plane (vectormetry; mA, mM,a.u.),andby pressuromodulation mapping of differentiated neuron cell sub-class operating range for neuroaxis gene expression in reference to tissue macro-compliance (Peff). Methods: The esebssiwaagoTQ effectivepressureunit(Peff) maxima and minima for horizontal gene intergene base segment tropy loop alignment were determined (n = 224); the Peff esebssiwaagoTQ quotient were determined (n =28)foranalysisof gene intergene base loop segment tropy structure nano-compliance (n = 28; n = 188); and gene positioning anglemetry and vectormetry was performed (n = 42). The sebs intercept-to-sebssiwa intercept quotient for linear normalization was determined (bsebs/bsebssiwa) by exponential plotting of sub-episode block sum (sebs) (x1, y1; x2, y2) and sub-episode block sum split integrated weighted average (sebssiwa) functions was performed, and the sebs – sebssiwa function residuals were determined.
    [Show full text]